ApoCell, Inc., was founded in 2004 by Dr. Darren Davis to commercialize translational biomarker research services for the biopharma industry and translational medical groups. The company was spun out of The University of Texas MD Anderson Cancer Center and operates a CLIA certified laboratory in the heart of the Houston, Texas medical center.  ApoCell contracts its translational research services with biopharma, academic and government labs, and CROs to develop biomarker assays and process clinical specimens to facilitate which drugs benefit the right patient. This collaborative approach is designed to advance investigational therapies through the regulatory agencies in an accelerated, cost-efficient manner.

Our unique platform technologies facilitate a deeper understanding of the pharmacodynamics of investigational therapies, enabling go / no-go decisions to be made much earlier in the drug development process. We use high content technologies like quantitative imaging, immunohistochemistry. flow cytometry and NGS  to answer challenging research questions. The company specializes in generating data to assess drug mechanism of action, optimal dosing schedules, identify biomarkers of resistance, and to facilitate patient stratification and companion diagnostic development, thereby enhancing clinical trial success.

Our expertise in creating data driven solutions is to integrate innovative platform technologies into complex workflows to optimize data generation. These complex workflows are essential for answering challenging translational research questions while preserving the amount of biological specimen needed to run the assay. Our approach allows us to investigate biomarkers using cutting-edge technologies in both ‘liquid biopsy’ and ‘tumor biopsy’ samples.

The Company has co-developed a proprietary, target cell enrichment platform technology, Apostream, with the National Cancer Institute (NCI) for isolating rare circulating tumor cells (CTCs) from whole blood for detecting pharmacodynamic biomarkers using serial blood samples. With unique capabilities to support advanced biomarker detection, the company has accelerated drug development for some of the world’s largest and most innovative pharmaceutical and biotechnology companies across different diseases including oncology and immuno-oncology, autoimmune and inflammatory, diabetes, infectious and regenerative medicine.

We are more than a provider of biomarker data. We are driven by the desire for more information, more insight, and more breadth and depth of analysis. We are a partner who will consult with you and work with you to design customized assays using cutting edge technologies for optimal data generation that is informative for accelerating your clinical pipeline.  Together with our partners, we are dedicated and committed to having the most beneficial impact for improving the lives of patients with debilitating diseases.